MedTrace Logo

Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas

NCT02763254 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2019-03-26

Study results available
· View outcomes & findings →

Summary

To investigate the efficacy of autologous Epstein-barr virus (EBV)-specific T cells for the treatment of EBV positive Diffuse Large B Cell Lymphoma (DLBCL), Hodgkin Lymphoma (HL) and Post-transplant Lymphoproliferative Disease (PTLD) after failing first line treatment.

Conditions

  • Hodgkin Lymphoma
  • Lymphoma, Large B-Cell, Diffuse
  • Post-transplant Lymphoproliferative Disorder

Interventions

BIOLOGICAL

baltaleucel-T

Autologous EBV-specific T cells

Sponsors & Collaborators

  • Cell Medica Ltd

    lead INDUSTRY

Principal Investigators

  • Kurt Gunter, MD · Cell Medica, Inc

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2018-02-17
Completion
2018-02-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02763254 on ClinicalTrials.gov